RE:RE:RE:RE:RE:substantially all Getinge receivables will flow through thisP.S.,
The European bank will be carrying the cost of this facility, for a small fee, of course, and there is a benefit to Getnge too as they getf to stretch out their date to pay receiveables to 90 as opposed to 45 days. So the EU bank associated with Getinge is confident in TOS and happy to support an exciting rapidly growing TSO3 with significant global blue sky future. A win, win, win.
Thus, “We anticipate substantially all Getinge receivables will flow through this program and appreciate collaborating with our partner to provide innovative solutions to fund our mutual growth and the continued global rollout of the STERIZONE® VP4 Sterilizer.” stated Kayll.
I place the emphasis on 'continued glosbal rollout'. as this confirms concentration on obtaining not just US market traction, but EU and important secondary markets like Dubai opening up to this first in class new low temperature techology solution.
I realise investors have been frustrated by TSo3's inabililty to provide colour on sell-through with Getinge in N. America due to Getinge's apparent policy of keeping the competition in the dark regarding which markets Getinge is acquiring at their competition's expense. Sales, technical, and medical facility support take time to build out and, we must be patient, there will be growing pains.
But, there can be no doubting this new and exciting standard of care sterilizer is being rolled out globally: Getinge, a truly global company with 15,000 employees is not only looking to hire 130+ US workers as they restructure, they are presenlly in the midst of showing support for and faith in the future of the VP4 by hiring an entire EU sales force dedicated to promoting, assisting, and supporting the roll-out of the VP4 Sterizone to lead Getinge's low temperature sterilization solution throughout the EU. Expansion of the VP4 solution in countries including Australia, New Zealsnd, and others in the Pacific Rim will not be far behind.